Audentes Therapeutics Inc. (NASDAQ:BOLD) and Sesen Bio Inc. (NASDAQ:SESN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation of the two firms.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Audentes Therapeutics Inc.||N/A||0.00||128.82M||-2.72||0.00|
|Sesen Bio Inc.||N/A||0.00||33.69M||-0.67||0.00|
Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Audentes Therapeutics Inc. and Sesen Bio Inc.
Table 2 shows the net margins, return on equity and return on assets of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Audentes Therapeutics Inc.||0.00%||-36.6%||-33.9%|
|Sesen Bio Inc.||0.00%||-85.7%||-33.6%|
The Current Ratio and a Quick Ratio of Audentes Therapeutics Inc. are 14.8 and 14.8. Competitively, Sesen Bio Inc. has 9.1 and 9.1 for Current and Quick Ratio. Audentes Therapeutics Inc.’s better ability to pay short and long-term obligations than Sesen Bio Inc.
Insider & Institutional Ownership
The shares of both Audentes Therapeutics Inc. and Sesen Bio Inc. are owned by institutional investors at 0% and 45.2% respectively. About 1.3% of Audentes Therapeutics Inc.’s share are owned by insiders. Comparatively, insiders own roughly 6.56% of Sesen Bio Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Audentes Therapeutics Inc.||18.9%||40.28%||43.46%||-2.66%||2.02%||63.18%|
|Sesen Bio Inc.||14.36%||30.32%||-43.45%||-50.26%||2.59%||-33.1%|
For the past year Audentes Therapeutics Inc. had bullish trend while Sesen Bio Inc. had bearish trend.
Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.